Nova Eye Medical (AU:EYE)
ASX:EYE
EYE Stock Chart & Stats
AU$0.13
-AU$0.01(-5.26%)
At close: 4:00 PM EST
AU$0.13
-AU$0.01(-5.26%)
Day’s Range― - ―
52-Week RangeAU$0.09 - AU$0.21
Previous CloseN/A
Volume155.74K
Average Volume (3M)204.72K
Market Cap
AU$37.03M
Enterprise ValueAU$39.35M
Total Cash (Recent Filing)AU$2.62M
Total Debt (Recent Filing)AU$4.94M
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding284,840,270
10 Day Avg. Volume176,528
30 Day Avg. Volume204,722
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)1.43
Price to Sales (P/S)0.93
P/FCF Ratio-4.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.01
Revenue Forecast (FY)AU$35.30M
Bulls Say, Bears Say
Bulls Say
Specialized Ophthalmic Product PortfolioNova Eye's focus on surgical devices and consumables for ophthalmology creates a specialized, high-knowledge business model with recurring consumable demand and clinical adoption cycles. This niche supports durable customer relationships, predictable procedure-driven revenue, and higher barriers to entry for competitors over months to years.
Low Financial LeverageA low debt-to-equity ratio provides financial flexibility to fund R&D, commercial rollout, and inventory without heavy interest burdens. Over a multi-month horizon this reduces insolvency risk, preserves optionality for strategic investments, and helps the company absorb operational setbacks while pursuing longer-term profitability.
Positive Revenue Growth TrendConsistent revenue growth demonstrates underlying market acceptance of products and expanding customer penetration. Sustained top-line growth supports scale benefits, potential margin recovery if cost control follows, and provides a foundation for eventual operating leverage and improved returns if maintained over the next several quarters.
Bears Say
Negative Operating Cash FlowPersistent negative operating and free cash flows signal the business is not self-funding operations and growth. Structurally, this pressures liquidity, forces dependence on external financing or equity dilution, and constrains investments in sales, marketing, and R&D needed to scale the ophthalmic product platform sustainably.
Declining Gross MarginsA sharp fall in gross margin indicates mounting cost pressures or pricing compression that directly undermines the unit economics of surgical products. If sustained, margin erosion reduces the path to profitability, limits reinvestment capacity, and increases sensitivity to volume fluctuations over the medium term.
Ongoing Negative ProfitabilityContinued negative net profit and EBIT margins reflect that operating performance has not yet turned to positive returns. Structurally, recurring losses depress ROE, limit retained capital for growth, and may necessitate repeated external funding, impairing shareholder value and constraining long-term strategic initiatives.
Nova Eye Medical News
EYE FAQ
What was Nova Eye Medical’s price range in the past 12 months?
Nova Eye Medical lowest share price was AU$0.09 and its highest was AU$0.20 in the past 12 months.
What is Nova Eye Medical’s market cap?
Nova Eye Medical’s market cap is AU$37.03M.
When is Nova Eye Medical’s upcoming earnings report date?
Nova Eye Medical’s upcoming earnings report date is Aug 27, 2026 which is in 151 days.
How were Nova Eye Medical’s earnings last quarter?
Nova Eye Medical released its earnings results on Feb 25, 2026. The company reported -AU$0.012 earnings per share for the quarter, missing the consensus estimate of -AU$0.005 by -AU$0.007.
Is Nova Eye Medical overvalued?
According to Wall Street analysts Nova Eye Medical’s price is currently Overvalued.
Does Nova Eye Medical pay dividends?
Nova Eye Medical pays a Weekly dividend of AU$0.414 which represents an annual dividend yield of N/A. See more information on Nova Eye Medical dividends here
What is Nova Eye Medical’s EPS estimate?
Nova Eye Medical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nova Eye Medical have?
Nova Eye Medical has 284,840,270 shares outstanding.
What happened to Nova Eye Medical’s price movement after its last earnings report?
Nova Eye Medical reported an EPS of -AU$0.012 in its last earnings report, missing expectations of -AU$0.005. Following the earnings report the stock price went down -3.125%.
Which hedge fund is a major shareholder of Nova Eye Medical?
Currently, no hedge funds are holding shares in AU:EYE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nova Eye Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:EYE Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $7.7K over
the Last 3 Months
the Last 3 Months
Fundamentals
Return on Equity
-44.16%
Trailing 12-Months
Asset Growth
-12.96%
Trailing 12-Months
Company Description
Nova Eye Medical
Nova Eye Medical Limited designs, develops, distributes, markets, sells, and services surgical devices for the treatment of glaucoma. The company offers iTrack, a surgical system for the reduction in intraocular pressure (IOP) in adult patients with open-angle glaucoma; iTrack Advance, a natural ocular drainage system; Molteno3, a glaucoma drainage device to treat patients with severe or complex glaucoma; and 2RT, a proprietary laser technology to treat patients in early/intermediate age-related macular degeneration. It operates in Australia, the United States, Europe, the Asia Pacific, and internationally. The company was formerly known as Ellex Medical Lasers Limited and changed its name to Nova Eye Medical Limited in July 2020. Nova Eye Medical Limited was founded in 1985 and is headquartered in Kent Town, Australia.
Technical Analysis
Compumedics Limited
―
Cyclopharm Limited
―
Micro-X Ltd.
―
EMvision Medical Devices Ltd.
―
Control Bionics Ltd.
―
Options Prices
Currently, No data available
---